2 Aug 2024 • In a first-of-its-kind trial, tirzepatide reduced severity of symptoms and improved heart failure outcomes in people with HFpEF and obesity.

Tirzepatide was approved by the FDA for adults with type 2 diabetes to improve glycemic control on May 13, 2022, and for adults with obesity (a BMI of 30 kg/m2 or greater) or those who are overweight (a BMI of 27 kg/m2 or greater) who also have a weight-related comorbid condition on November 8, 2023.

In the SUMMIT Phase III trial, injection with tirzepatide (5 mg, 10 mg or 15 mg) was tested as a possible treatment for heart failure with preserved ejection fraction in obese patients.

• Tirzepatide demonstrated statistically significant improvements in both primary endpoints with a reduction in the risk of heart failure outcomes as welll as improvements in heart failure symptoms and physical limitations.
• When assessing body weight changes, the efficacy estimated indicated patients receiving tirzepatide experienced a mean reduction in body weight of 15.7% vs 2.2% for placebo.

Source: Press Release | Read full story